Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Common Equity (2020 - 2025)

Historic Common Equity for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $276.0 million.

  • RxSight's Common Equity fell 46.56% to $276.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $276.0 million, marking a year-over-year decrease of 46.56%. This contributed to the annual value of $281.2 million for FY2024, which is 7537.7% up from last year.
  • As of Q3 2025, RxSight's Common Equity stood at $276.0 million, which was down 46.56% from $278.0 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Common Equity ranged from a high of $281.2 million in Q4 2024 and a low of -$313.4 million during Q2 2021
  • For the 5-year period, RxSight's Common Equity averaged around $158.3 million, with its median value being $158.8 million (2023).
  • The largest annual percentage gain for RxSight's Common Equity in the last 5 years was 13509.49% (2022), contrasted with its biggest fall of 3640.51% (2022).
  • Quarter analysis of 5 years shows RxSight's Common Equity stood at $138.2 million in 2021, then tumbled by 34.97% to $89.9 million in 2022, then skyrocketed by 78.37% to $160.4 million in 2023, then skyrocketed by 75.38% to $281.2 million in 2024, then fell by 1.87% to $276.0 million in 2025.
  • Its Common Equity stands at $276.0 million for Q3 2025, versus $278.0 million for Q2 2025 and $279.3 million for Q1 2025.